Search results for: "Novo Nordisk"

(167 records)

Research & Development
A new era in diabetes: five biotech companies moving past daily insulin injections

A new era in diabetes: five biotech companies moving past daily insulin injections

From cell-encapsulation platforms and islet transplantation breakthroughs to next-generation GLP-1 combinations and connected insulin delivery, a new wave of biotech innovation...
Media
Alzheimer's Association comments on failed Novo Nordisk GLP-1 trial

Alzheimer's Association comments on failed Novo Nordisk GLP-1 trial

The company said the results from the evoke study, which tested an oral semaglutide pill for early-stage symptomatic Alzheimer's disease, were "not what we had hoped for"
Research & Development
Novo Nordisk’s oral semaglutide fails to slow Alzheimer’s progression in global Phase III trials

Novo Nordisk’s oral semaglutide fails to slow Alzheimer’s progression in global Phase III trials

The studies showed no statistically significant benefit on disease progression despite biomarker improvements, leading to a sharp drop in the company's share price
Finance
Pfizer clinches $10bn deal to acquire weight-loss biotech Metsera after bidding war with Novo Nordisk

Pfizer clinches $10bn deal to acquire weight-loss biotech Metsera after bidding war with Novo Nordisk

Metsera says that it has opted for Pfizer's revised deal after antitrust concerns surrounding rival Novo's bid for the biotech
Research & Development
Novo Nordisk's Wegovy results in patients hitting key BMI and waist size targets

Novo Nordisk's Wegovy results in patients hitting key BMI and waist size targets

New STEP UP trial data show that semaglutide enables people with obesity to achieve BMI and waist-to-height ratio targets linked to lower cardiovascular risk, alongside...
Finance
Pfizer denied restraining order on rival Novo Nordisk in GLP-1 bidding war

Pfizer denied restraining order on rival Novo Nordisk in GLP-1 bidding war

The Delaware Chancery Judge rejected Pfizer's request for a temporary restraining order, arguing that the company's objections to Novo's proposed deal weren't a legitimate...
Finance
Metsera declares $10bn Novo deal "superior" after Pfizer files second lawsuit in GLP-1 row

Metsera declares $10bn Novo deal "superior" after Pfizer files second lawsuit in GLP-1 row

Metsera has said Novo Nordisk’s revised offer is a “superior proposal” to Pfizer’s, escalating a high-stakes legal and acquisition battle and where Pfizer has filed a...
Finance
Pfizer sues Metsera and Novo Nordisk over alleged breach of merger agreement

Pfizer sues Metsera and Novo Nordisk over alleged breach of merger agreement

Pfizer has filed a lawsuit against Metsera, its Board of Directors and Novo Nordisk, alleging breach of contract, fiduciary duty and interference following Metsera’s decision...
Finance
Novo Nordisk acquires rights to Omeros’ MASP-3 inhibitor zaltenibart in $2.1bn deal

Novo Nordisk acquires rights to Omeros’ MASP-3 inhibitor zaltenibart in $2.1bn deal

The agreement grants Novo Nordisk exclusive global rights to develop and commercialise the clinical-stage antibody for rare blood and kidney disorders, strengthening its Rare...
Regulatory
Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Research & Development
Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other...
Drug Delivery
BioMed X and Novo Nordisk launch new collaboration in oral peptide drug delivery

BioMed X and Novo Nordisk launch new collaboration in oral peptide drug delivery

The initiative aims to identify and support new ideas for innovative oral formulations for peptide drugs such as GLP-1 receptor agonists via BioMed X’s global talent sourcing...
Wegovy approved by FDA to treatment adults with non-cirrhotic MASH with moderate to advanced liver fibrosis

Wegovy approved by FDA to treatment adults with non-cirrhotic MASH with moderate to advanced liver fibrosis

The FDA has granted approval for Wegovy (semaglutide) injection 2.4 mg as the first GLP-1 receptor agonist to treat adults with moderate to advanced liver scarring because of...
Research & Development
Novo Nordisk's Wegovy effective in obese patients, Phase IIIb data suggests

Novo Nordisk's Wegovy effective in obese patients, Phase IIIb data suggests

A 7.2mg dose of semaglutide triggered an average weight loss of 21% in obese patients during a 72 week period
Finance
Weight loss drugs fuelling rapid big pharma growth, report reveals

Weight loss drugs fuelling rapid big pharma growth, report reveals

Weight loss and diabetes medications are championing growth in key big pharma players, such as Novo Nordisk and Eli Lilly
Finance
Novo Holdings completes acquisition of Catalent

Novo Holdings completes acquisition of Catalent

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark

Trending Articles

  1. Loftware and RiseNow partner to strengthen supply chain traceability and compliance in healthcare settings The alliance pairs Loftware's SAP-integrated product identification platform with RiseNow's procurement and supply chain advisory services, delivering end-to-end track-and-trace capabilities for regulated industries where audit readiness and patient safety are critical
  2. Bausch and Lomb hit with FDA Warning Letter for persistent microbial contamination The regulator cited persistent out-of-limit microbial recoveries in ISO 5 areas, deficiencies in aseptic processing and airflow controls and an ineffective quality system at Bausch and Lomb's Tampa manufacturing facility
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Japanese researchers report advances in liver disease treatment and cancer screening Two research teams in Japan have published findings that could open new avenues in metabolic disease treatment and non-invasive cancer screening
  4. FDA approves Telix’s first FET-PET imaging drug for glioma Telix’s Pixclara is the first FDA-approved FET-PET imaging agent for glioma, enabling US clinicians to distinguish recurrent or progressive brain tumours from treatment-related changes
  5. Exceptional excipients enabled with expertise Growing regulatory expectations, increasing pressure to secure resilient regional supply chains and the need for more efficient manufacturing are reshaping how medicines are developed and produced

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Manufacturing The platform supports pharmaceutical companies in developing, evaluating and optimising formulations and processes for continuous manufacturing
DFE Pharma to showcase its Continuous Manufacturing Platform at CPHI Milan 2026

DFE Pharma to showcase its Continuous Manufacturing Platform at CPHI Milan 2026

Read more
Manufacturing Enzene is a CIDMO partner supporting innovators and biosimilar developers from discovery to commercial supply with integrated, paradigm-changing biologics services and...
Enzene: Bringing the most advanced innovations to biologics manufacturing

Enzene: Bringing the most advanced innovations to biologics manufacturing

Read more
Research & Development The collaboration combines human-relevant in vitro immunology with in vivo pharmacology to support biotech drug discovery programmes, including endometriosis research
Oncodesign Services and Nexus BioQuest partner on preclinical drug development

Oncodesign Services and Nexus BioQuest partner on preclinical drug development

Read more
Manufacturing UK CDMO Upperton can now manufacture sterile investigational medicinal products at its new 7,000 sq ft facility in Nottingham, expanding its GMP clinical supply capabilities
Upperton gains MHRA licence for Annex 1-aligned sterile facility

Upperton gains MHRA licence for Annex 1-aligned sterile facility

Read more
Pharma 5.0 The next phase of AI adoption in pharma could be less about discovering new medicines and more about tackling the operational barriers that prevent AI projects from scaling,...
Beyond drug discovery: the untapped value of AI in pharma operations

Beyond drug discovery: the untapped value of AI in pharma operations

Read more
Manufacturing As demand for HPAPIs and highly potent drug products grows, the pharmaceutical industry faces increasing pressure to combine containment, product and operator protection,...
Beyond containment: integrated line design reduces risk and complexity

Beyond containment: integrated line design reduces risk and complexity

Read more
Manufacturing Free in-person workshop combines expert theory with hands-on laboratory sessions to build confidence in viscosity measurement
Anton Paar’s popular viscosity workshop returns to Luton this October

Anton Paar’s popular viscosity workshop returns to Luton this October

Read more
Manufacturing New spray drying, dry granulation and pharmaceutical development solutions showcased at CPHI Milan
Glatt presents integrated particle engineering solutions at CPHI Milan

Glatt presents integrated particle engineering solutions at CPHI Milan

Read more